Volume 143, Issue 3, Pages e2 (September 2012)

Slides:



Advertisements
Similar presentations
MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma  Jinyan Du, Arlo J. Miller, Hans R. Widlund, Martin.
Advertisements

C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades  Yi-Chao Shi, Hong Zhao, Chuan Yin, Xin Zeng, Qing Zhang, Wen-Ping Xu, Ji.
Volume 139, Issue 3, Pages e8 (September 2010)
Volume 145, Issue 4, Pages e2 (October 2013)
Volume 139, Issue 6, Pages e12 (December 2010)
Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling  Baoping Cao, MD, PhD, Weili Yang,
Volume 144, Issue 3, Pages e4 (March 2013)
Volume 145, Issue 2, Pages (August 2013)
Volume 145, Issue 4, Pages e9 (October 2013)
A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
Volume 142, Issue 4, Pages e3 (April 2012)
Crucial Roles of MZF1 and Sp1 in the Transcriptional Regulation of the Peptidylarginine Deiminase Type I Gene (PADI1) in Human Keratinocytes  Sijun Dong,
Volume 140, Issue 2, Pages e2 (February 2011)
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression  Dongdong Lu, Chang Han, Tong.
Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis  Ruo-Chia Tseng, PhD, Jia-Ming Chang,
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
Volume 133, Issue 6, Pages (December 2007)
Volume 128, Issue 1, Pages (January 2005)
Volume 136, Issue 2, Pages e1 (February 2009)
Volume 137, Issue 2, Pages e2 (August 2009)
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Volume 138, Issue 3, Pages e2 (March 2010)
Volume 128, Issue 7, Pages (June 2005)
Volume 145, Issue 4, Pages e9 (October 2013)
Volume 143, Issue 5, Pages (November 2012)
Volume 54, Issue 4, Pages (October 2008)
Volume 146, Issue 7, Pages e5 (June 2014)
Epigenetic Inhibition of Nuclear Receptor Small Heterodimer Partner Is Associated With and Regulates Hepatocellular Carcinoma Growth  Nan He, Kyungtae.
Volume 139, Issue 6, Pages e12 (December 2010)
Volume 139, Issue 6, Pages (December 2010)
Volume 142, Issue 3, Pages (March 2012)
Teruaki Fujishita, Masahiro Aoki, Makoto M. Taketo  Gastroenterology 
Volume 141, Issue 6, Pages (December 2011)
Volume 145, Issue 4, Pages e2 (October 2013)
Volume 134, Issue 1, Pages (January 2008)
Volume 140, Issue 1, Pages e2 (January 2011)
Volume 144, Issue 1, Pages e4 (January 2013)
Volume 145, Issue 2, Pages e6 (August 2013)
Volume 135, Issue 5, Pages e3 (November 2008)
Volume 136, Issue 2, Pages (February 2009)
Laminin γ2 Mediates Wnt5a-Induced Invasion of Gastric Cancer Cells
Sp1 Is Required for Glucose-Induced Transcriptional Regulation of Mouse Vesicular Glutamate Transporter 2 Gene  Tao Li, Liqun Bai, Jing Li, Suzu Igarashi,
Volume 139, Issue 3, Pages e8 (September 2010)
Volume 138, Issue 2, Pages e2 (February 2010)
Volume 133, Issue 5, Pages (November 2007)
Volume 143, Issue 6, Pages e5 (December 2012)
Volume 147, Issue 5, Pages (November 2014)
Volume 138, Issue 5, Pages e2 (May 2010)
Volume 140, Issue 4, Pages e1 (April 2011)
Volume 142, Issue 3, Pages e2 (March 2012)
Volume 145, Issue 2, Pages (August 2013)
Volume 140, Issue 3, Pages (March 2011)
Tomoyasu Hattori, Lukasz Stawski, Sashidhar S
Volume 137, Issue 1, Pages (July 2009)
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2  Ji-guang Zhang,
Volume 142, Issue 2, Pages (February 2012)
Volume 142, Issue 7, Pages e2 (June 2012)
Volume 135, Issue 3, Pages e3 (September 2008)
Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk  Xinyu Yang, Dianke Yu, Yanli Ren, Jinyu Wei, Wenting.
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
Volume 147, Issue 5, Pages (November 2014)
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression  Dongdong Lu, Chang Han, Tong.
Volume 132, Issue 4, Pages (April 2007)
Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor  Dai Iwakiri, Daniel K. Podolsky 
A Novel Role of Transforming Growth Factor β1 in Transcriptional Repression of Human Cholesterol 7α-Hydroxylase Gene  Tiangang Li, John Y.L. Chiang  Gastroenterology 
A LIN28B Tumor-Specific Transcript in Cancer
Volume 128, Issue 3, Pages (March 2005)
Volume 127, Issue 4, Pages (October 2004)
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 4, Pages (April 2017)
Presentation transcript:

Volume 143, Issue 3, Pages 799-810.e2 (September 2012) Dysregulated Krüppel-Like Factor 4 and Vitamin D Receptor Signaling Contribute to Progression of Hepatocellular Carcinoma  Qi Li, Yong Gao, Zhiliang Jia, Lopa Mishra, Kun Guo, Zhiwei Li, Xiangdong Le, Daoyan Wei, Suyun Huang, Keping Xie  Gastroenterology  Volume 143, Issue 3, Pages 799-810.e2 (September 2012) DOI: 10.1053/j.gastro.2012.05.043 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 KLF4 expression in HCC cells and tissues. (A) Total protein lysates were harvested from a panel of HCC cell line cultures and normal liver tissues, and KLF4 protein expression was measured by Western blot analysis (Ai). The relative KLF4 expression was expressed as a ratio between KLF4 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (normal tissues were given 100%, Aii). (B) KLF4 immunostaining of HCC TMA sections. Pearson 2-tailed χ2 test showed a significant statistical difference in KLF4 protein expression among the 3 tissue types (*P < .05; #P < .01). (C) KLF4 messenger RNA (mRNA) (quantitative polymerase chain reaction, Ci) and protein (Western blot, Cii) expression in HCC tissues. Representative photos of KLF4 protein expression in HCC are shown (Ciii). The majority of the adjacent normal liver tissue cells (N) were strongly positive for KLF4 expression, whereas HCC cells (T) were negative. (D) Genomic DNA extracted from HCC cell lines (Di), HCC tissues (T), and the matched normal liver tissues (N, Dii). Methylation-specific polymerase chain reaction was performed using primers specific for the unmethylated (U) or methylated (M) KLF4 exon 1 region in the genomic DNA. (E) Reactivation of KLF4 expression. Cells were cultured in the presence of 5-Aza-2′-deoxycytidine (1 μmol/L) for 3 days. Total RNA was extracted, and KLF4 expression was measured by reverse-transcription polymerase chain reaction (Ei), quantitative polymerase chain reaction (Eii), and Western blot (Eiii). Gastroenterology 2012 143, 799-810.e2DOI: (10.1053/j.gastro.2012.05.043) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 The effect of KLF4 expression on HCC growth in vitro and in vivo. (A–C) In vitro growth. SK-Hep-1 and Hep-G2 cells were transduced with Ad-KLF4 or a control Ad-EGFP for 24 to 96 hours. Cell growth was determined by cell counting. Representative photos of SK-Hep-1 cell morphology changes are shown. (D and E) In vivo growth. SK-Hep-1 (D) and Hep-G2 (E) cells were transduced with 10 multiplicity of infection of Ad-KLF4 or a control Ad-EGFP and injected into the subcutis of groups of mice (n = 10). Tumors were harvested 45 days after tumor injections and weighed. Shown from each group are representative mouse with tumors (Di and Ei), 3 gross tumors (Dii and Eii), and mean (±standard deviation) tumor weights (Diii and Eiii). This representative experiment is 1 of 2 with similar results. *P < .05. Gastroenterology 2012 143, 799-810.e2DOI: (10.1053/j.gastro.2012.05.043) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 Inhibition of HCC metastasis by KLF4. SK-Hep-1 and Hep-G2 cells with mock transduction, control Ad-EGFP, or Ad-KLF4 were implanted in the subcutis of nude mice (n = 10). Numbers and sizes of liver metastases were determined (Ai and Aii: SK-Hep-1). Also shown are a representative mouse with a subcutaneous tumor and liver metastases (white arrow, Bi) and gross liver metastases (yellow arrows) from the groups injected with SK-Hep-1 cells (Bii). The cells were also injected intravenously via the ileocolic veins of groups of mice (n = 10), and liver metastases were determined 45 days after tumor cells injections. Numbers of liver metastases were determined (C: SK-Hep-1). Also shown are representative photos of liver micrometastases (yellow arrows) (D: Hep-G2). Gastroenterology 2012 143, 799-810.e2DOI: (10.1053/j.gastro.2012.05.043) Copyright © 2012 AGA Institute Terms and Conditions

Figure 4 Inhibition of HCC cell migration and invasion by KLF4. (A) SK-Hep-1 and Hep-G2 cells were transduced with 10 multiplicity of infection of Ad-KLF4 or a control Ad-EGFP. Total protein lysates were harvested from the cultures; expression of KLF4 protein and EMT markers was measured by Western blot analyses (Ai), and morphologic changes are shown for SK-Hep-1 cells (Aii). (B) Total protein lysates were harvested from the HCC xenograft tumors, and expression of KLF4 protein and EMT markers was measured by Western blot analyses (Bi) and immunostaining (Bii). Gap closing (C), migration (D), and invasion (E) of tumor cells were determined as described in Materials and Methods section. The untreated cell cultures were given arbitrary migration and invasiveness percentages of 100%. Representative photos of cell migration and invasion were shown. *P < .001 in a comparison of the KLF4-treated group with the control and Ad-EGFP-treated groups. This representative experiment is 1 of 3 with similar results. Gastroenterology 2012 143, 799-810.e2DOI: (10.1053/j.gastro.2012.05.043) Copyright © 2012 AGA Institute Terms and Conditions

Figure 5 Direct association of VDR expression with KLF4 expression. (A) SK-Hep-1 and Hep-G2 were transduced with Ad-KLF4 (KLF4) or control Ad-EGFP (EGFP) at a 10 multiplicity of infection (Ai) or KLF4 small interfering RNA (siRNA) (Aii) and incubated for 24 hours. Total protein lysates were harvested, and VDR and KLF4 expression was determined using Western blotting. (B) Sensitivity of HCC cells to VD3. (C) Three sets of consecutive TMA sections were prepared for immunostaining using specific antibodies against VDR and KLF4. Representative photos of VDR and KLF4 protein expression in HCC and adjacent normal liver cells (original magnification, 50× for left panels; 200× for right panels, Ci). The VDR expression levels directly correlated with the KLF4 expression levels (Pearson χ2 test, P < .001) in primary HCC (Cii). (D) KLF4 and VDR protein expression levels in HCC cells were determined by Western blot analysis (Di). Growth inhibition of HCC cells by VD3 (P < .001, t test, Dii). (E) The survival rates were estimated using the Kaplan–Meier method: the KLF4 expression and patient survival (Ei, rates in patients with KLF4-negative primary tumors were significantly worse than those in patients with strong KLF4-positive primary tumors) and the VDR expression levels and patient survival (Eii, no significant difference among different groups). Gastroenterology 2012 143, 799-810.e2DOI: (10.1053/j.gastro.2012.05.043) Copyright © 2012 AGA Institute Terms and Conditions

Figure 6 Up-regulation of VDR expression by KLF4 in HCC cells. (A) Schematic structure of the VDR promoter reporter and its deletion- and point-mutation reporters and sequences of chromatin immunoprecipitation (ChIP) primers are shown (Ai). The VDR promoter reporter and mutations of it in KLF4-binding site 1 (K1), KLF4-binding site 2 (K2), or both (K1/2) were transfected into Hep-3B cells in triplicate. The relative VDR promoter activities were measured 24 hours after transfection, and the activities in the treated groups were expressed as the fold of that in their respective control groups (Aii). (B) The VDR promoter reporter was transfected into SK-Hep-1 and Hep-G2 cells in triplicate with pKLF4, and mock transfection or transfection with pcDNA3 were used as controls (Bi) or KLF4 small interfering RNA (siRNA) (Bii). Similarly, VDR promoter activities were determined in various HCC cell lines (Biii). (C) Chromatin was extracted from Hep-1 (Ci) and Hep-G2 (Cii) cells or Hep-G2 cells treated with KLF4 small interfering RNA (siRNA) or Ad-KLF4 (Ciii). A ChIP assay was performed using a specific anti-KLF4 antibody and oligonucleotides flanking the VDR promoter regions containing putative KLF4-binding sites. The nucleotide positions and sequences of the polymerase chain reaction forward and reverse primers flanking those sites in the ChIP assay are described in Materials and Methods section. Gastroenterology 2012 143, 799-810.e2DOI: (10.1053/j.gastro.2012.05.043) Copyright © 2012 AGA Institute Terms and Conditions